Welcome to our dedicated page for Humacyte SEC filings (Ticker: HUMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Humacyte, Inc. filings document a commercial-stage biotechnology issuer built around acellular tissue engineered vessels and related bioengineered human tissue programs. Its reports and 8-K filings cover operating results, product commercialization, clinical and regulatory disclosures, material agreements for Symvess distribution rights, and collaboration or licensing arrangements.
The company’s SEC record also includes capital-structure disclosures for common stock and redeemable warrants, equity offering arrangements, secured debt financing, and Nasdaq listing-rule notices. Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and other governance disclosures for HUMA.
Humacyte, Inc. director Kathleen Sebelius reported an open-market purchase of 56,818 shares of Humacyte common stock at a price of $0.88 per share on May 19, 2026. Following this transaction, she directly holds a total of 148,025 Humacyte common shares.
Humacyte, Inc. director Michael T. Constantino reported an open-market purchase of common stock. On May 18, 2026, he bought 11,000 shares of Humacyte common stock at a weighted average price of $0.8945 per share in multiple transactions.
Following this purchase, Constantino directly owns 43,950 common shares. The filing notes that the trades were executed across a price range from $0.8922 to $0.8958 per share and that detailed trade-by-trade pricing is available upon request.
Humacyte, Inc. CFO and Chief Corporate Development Officer Dale A. Sander reported an automated sale of 45,887 shares of common stock at an average price of $0.8967 per share. The sale was executed solely to cover statutory tax withholding from vested restricted stock units under a pre-arranged Rule 10b5-1 sell-to-cover plan, not as a discretionary sale. After this transaction, he holds 267,213 shares directly and 40,600 shares indirectly through his spouse.
Humacyte, Inc.'s Chief Medical Officer, Shamik J. Parikh, reported an automated sale of 45,887 shares of common stock at an average price of $0.8967 per share.
The filing explains this was a mandatory “sell-to-cover” transaction to fund statutory tax withholding tied to vesting of restricted stock units, carried out under a Rule 10b5-1(c) trading plan and not a discretionary sale. After this tax-related sale, Parikh directly holds 272,713 shares of Humacyte common stock.
Humacyte, Inc. reported a net loss of $17.6 million for the quarter ended March 31, 2026, compared with net income of $39.1 million a year earlier, as favorable fair value movements on earnout and warrant liabilities were much smaller than in 2025.
Total revenue was $0.5 million, with product revenue from Symvess increasing to $493,000 while contract revenue declined. Operating expenses rose to $29.4 million, driven mainly by higher research and development spending of $19.5 million.
Humacyte used $25.1 million of cash in operating activities and ended the quarter with cash and cash equivalents of $48.5 million. Management states that these resources are not sufficient to fund operations beyond one year without stronger Symvess sales and/or additional financing, raising substantial doubt about the company’s ability to continue as a going concern.
Humacyte, Inc. received a Nasdaq notice that its common stock bid price was below the required $1.00 per share for 30 consecutive business days ended May 1, 2026, putting it out of compliance with Nasdaq Listing Rule 5450(a)(1).
The company has 180 calendar days, until November 2, 2026, for its closing bid price to be at least $1.00 per share for a minimum of 10 consecutive business days to regain compliance. Trading of the stock and the company’s operations and SEC reporting continue unchanged for now, but there is explicit delisting risk if compliance is not restored.
Humacyte, Inc. is asking stockholders at its virtual annual meeting on June 9, 2026 to approve six items, including electing three Class II directors and an advisory vote on executive pay and its frequency. Stockholders will also vote on ratifying PricewaterhouseCoopers LLP as auditor for 2026 and increasing authorized common stock from 350,000,000 to 550,000,000 shares via a charter amendment. Shares outstanding were 222,019,108 as of April 23, 2026, the record date. The proxy outlines governance practices, committee structures, and 2025 compensation, including bonuses paid at 80% of target and significant stock option and RSU grants to senior executives.
Humacyte, Inc. and Fresenius Medical Care have amended their 2018 distribution agreement for Symvess, an acellular tissue engineered vessel. Humacyte now has exclusive rights to distribute Symvess outside the U.S., while Fresenius Medical Care Holdings, Inc. will receive low-single-digit royalties on ex-U.S. net sales.
Existing terms for U.S. distribution remain unchanged. Fresenius Medical Care Holdings, Inc. and its parent, Fresenius Medical Care, report beneficial ownership of 18,312,735 shares of Humacyte common stock, representing 8.4% of the class, all with shared voting and dispositive power.